Walleye Trading 13F: Cuts ABVX Stake by $1.1M

Walleye Trading has significantly reduced its investment in ABIVAX Société Anonyme (NasdaqGM: ABVX). The firm cut its position by 45.3%, selling 8,117 shares to hold 9,769 shares as of the latest filing period. The value of Walleye Trading's remaining stake in the biotechnology company is approximately $1.3 million, based on the latest Form 13F filing with the SEC.

What Changed in Walleye Trading's ABIVAX Position

Walleye Trading decreased its holdings in ABIVAX from 17,886 shares to 9,769 shares, a reduction of 8,117 shares. This move represents a 45.3% decrease in its stake, with the total value of the remaining shares now at about $1.3 million.

Other Institutional Activity in ABIVAX

Several other institutional investors have also adjusted their positions in ABIVAX. TCG Crossover Management, LLC reduced its stake by 630,511 shares, leaving it with 6,481,085 shares valued at $721.7 million, an 8.9% decrease. UBS Group AG, on the other hand, increased its holdings by 123,500 shares to a total of 4,547,406 shares, worth approximately $506.4 million, reflecting a 2.8% increase. Darwin Global Management, Ltd. boosted its position by 290,156 shares, now holding 3,468,657 shares valued at $352.1 million, marking a 9.1% increase. Meanwhile, Morgan Stanley cut its holdings by 1,447,036 shares, a 45.9% reduction, ending with 1,704,958 shares worth $189.8 million. Vestal Point Capital, LP also trimmed its position by 400,000 shares, a 21.1% decrease, to hold 1,500,000 shares valued at $167 million.

ABIVAX Société Anonyme Stock Up 51.0%

Shares of ABIVAX traded near $132.83 on Wednesday. The company, with a market capitalization of around $10.6 billion, operates in the biotechnology sector. It has a forward P/E ratio of -40.8, indicating it isn't currently profitable. The stock's 52-week range is between $7.41 and $148.83, with a 50-day moving average of $111.05 and a 200-day moving average of $111.25. ABIVAX's beta is -0.2, suggesting lower volatility compared to the broader market. The company maintains a current ratio of 8.25 and a quick ratio of 8.07, with a debt-to-equity ratio of 7.96.

Recent Earnings

ABIVAX reported revenue of $4.92 million, reflecting a growth rate of 35.2%. However, the company posted a negative return on equity of -1.57 and has no meaningful net margin. The next earnings report is expected on September 21, 2026.

Insider Buying and Selling at ABIVAX Société Anonyme

Insider activity shows that Sofinnova Crossover sold 1,000,000 shares at an average price of $133.70 on January 8, 2026. Earlier transactions include Sofinnova Crossover SLP selling 1,200,000 shares at $92.75 on October 28, 2025, without any planned sales.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for ABIVAX. On June 30, 2026, Jefferies upgraded the stock to a "buy" rating with a $158 price target. BTIG maintained its "buy" rating with a $175 target, while Leerink Partners also maintained a "buy" with a $148 target. The consensus recommendation for ABIVAX is a "buy," with a mean price target of $150.73 based on 11 analyst opinions.

About ABIVAX Socie9te9 Anonyme

ABIVAX Société Anonyme is a biotechnology company based in Paris, France. It focuses on developing therapeutics that leverage the body's natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. Its primary drug candidate, obefazimod, is in Phase 3 development for ulcerative colitis and Phase 2b trials for Crohn's disease. Founded in 2013, the company is led by CEO Marc de Garidel and employs around 80 people.

Bottom Line

The reduction in Walleye Trading's position in ABIVAX highlights a significant shift in its investment strategy. Investors often watch these filings to gauge institutional sentiment, but it's important to remember that 13F filings reflect past positions and may not represent current holdings. With analysts maintaining positive outlooks, ABIVAX remains an interesting company to watch in the biotech sector.